Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated ...

Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 ...

Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...

Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...

The phase 3 TiNivo-2 study (NCT04987203), which evaluated the combination of nivolumab (Opdivo) and tivozanib (Fotivda) in ...

Tempest Therapeutics Inc (NASDAQ: TPST) has experienced a rise in its stock price by 5.04 compared to its previous closing price of 1.19. However, the company has seen a fall of -6.72% in its stock ...

Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated ...

Among those it is feared could face the chop is the multibillion-pound Tempest fighter jet programme which is set to build the UK's future flagship fighter jet in partnership with Japan and Italy.

A canyon created by floodwaters.Credit...Michael Lundgren for The New York Times Supported by By Terry Tempest Williams Photographs by Michael Lundgren Ms. Williams lives in southeastern Utah and ...

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations.